By proceeding, you agree to our Terms of Use and Privacy Policy.
Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design.
06-07 September 2023
LSX are known for bringing life science investors together to assess and meet with the most promising up-and-coming biotech companies. When the first mRNA vaccines hit the market in 2020, one of our investors asked us to look at the resurgence of the
Event Ended
USA
Paid
Boston